Context Therapeutics

Yahoo Finance • 15 days ago

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that Context has granted non-qualifi... Full story

Yahoo Finance • 20 days ago

Context Therapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate... Full story

Yahoo Finance • last year

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, Nov. 09, 2023... Full story

Yahoo Finance • last year

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the Company’s pr... Full story

Yahoo Finance • 2 years ago

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

CTIM-76 IND filing on track for Q1 2024 Preclinical data on CLDN6 bispecific antibody CTIM-76 presented at AACR Annual Meeting 2023 Cash and cash equivalents of $29.8 million as of March 31, 2023 PHILADELPHIA, May 10, 2023 (GLOBE NEWS... Full story

Yahoo Finance • 2 years ago

Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Emerging Growth Invitational Investor Conference on April 5, 2023. The... Full story

Yahoo Finance • 2 years ago

Context Therapeutics to Participate in Two April 2023 Investor Conferences

PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced that Chief Executive Office... Full story

Yahoo Finance • 2 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on fema... Full story

Yahoo Finance • 2 years ago

UPDATE -- Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX)

NEW YORK, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Context Therapeutics Inc. (NASDAQ: CNTX). The in-depth 26... Full story

Yahoo Finance • 2 years ago

Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX)

NEW YORK, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Context Therapeutics Inc. (NASDAQ: CNTX). The in-depth 26... Full story

Yahoo Finance • 2 years ago

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage ONA-XR continues to be safe and well-tolerated PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”)... Full story

Yahoo Finance • 2 years ago

Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast cancer ORSERDU is being evaluated in combination with Context’s ONA-XR in the ongoing ELO... Full story

Yahoo Finance • 2 years ago

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer PFS follows recently disclosed positive preliminary data in... Full story

Yahoo Finance • 2 years ago

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host webinar on Thursday, December 1, 2022, at 11 a.m. ET PHILADELPHIA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Context Thera... Full story

Yahoo Finance • 2 years ago

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

PHILADELPHIA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, today announced clinical da... Full story

Yahoo Finance • 2 years ago

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Company reports preliminary ONA-XR data from two ongoing Phase 2 trials ONA-XR demonstrates preliminary 4-month PFS rate of 77.7% in ongoing Phase 2 trial evaluating the combination of ONA-XR and the antiestrogen anastrozole in PR+ recurr... Full story

Yahoo Finance • 3 years ago

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models First presentation of preclinical CLDN6xCD3 bispecific antibody optimization, binding properties, an... Full story